Phase 1
Completed N=25
Study of the Safety of QRH-882260 Heptapeptide
Healthy Adults
Source: ClinicalTrials.gov NCT02574858 ↗
Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcomePrimary: Number of Subjects With Abnormal Lab Values — 1 Participants
Summary
The purpose of this study is to evaluate the safety of orally administered QRH-882260, a topically administered Cy5-labeled heptapeptide specific for epithelial growth factor receptor (EGFR).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects With Abnormal Lab Values |
1 | — |
| PRIMARY Number of Subjects With Abnormal EKG |
— | — |
Eligibility Criteria
Inclusion Criteria
- Adults age 25 to 100 years
- Not pregnant (willing to have pregnancy test if applicable)
- No recent illness (infection, URI, virus or flu) within 2 weeks,
- Stable health status (i.e. no medication changes within 2 months, no recent surgery, etc. per PI)
- Willing and able to sign informed consent
- Willing and able to drink the peptide and a tap water chaser
- Willing and able to get baseline and 24-48 hours post ingestion labs Exclusion Criteria
- Known allergy to Cy5 or derivatives, such as indocyanine green (ICG)
- Subjects on active chemotherapy or radiation therapy
- Diabetics on insulin/hypoglycemic (due to fasting requirements)
Data sourced from ClinicalTrials.gov (NCT02574858). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.